Please login to the form below

Not currently logged in
Email:
Password:

Astellas files combination urology product EC905 in Europe

Netherlands filing to treat symptoms of benign prostatic hyperplasia paves way for rest of Europe

Astellas Pharma has filed for approval of a new drug to treat the symptoms of benign prostatic hyperplasia (BPH) in the Netherlands, starting the process for EU-wide registration.

The new product, called EC905, is a fixed-dose combination of solifenacin and tamsulosin and has been filed with a proposed indication of treating lower urinary tract symptoms (LUTS) associated with BPH.

EC905 combines the active ingredients of two of Astellas' top-selling products, namely Harnal (tamsulosin) and Vesicare (solifenacin succinate).

To date BPH patients have often had to take a combination of different products to manage their symptoms effectively, and EC905 aims to reduce pill burden and maintain efficacy and tolerability.

The Dutch filing is based on the results of the phase III NEPTUNE study, which were presented at the end of February at the European Association of Urology congress in Paris.

In that study, EC905 improved LUTS in men aged over 45 with both voiding and storage symptoms, performing better than both placebo and tamsulosin monotherapy.

LUTS are common in men and include symptoms of voiding, including hesitancy and intermittency, as well as storage symptoms (frequency, urgency, nocturia) and feelings of incomplete bladder emptying.

In a study of four European countries plus Canada, LUTS was found to affect more than 60 per cent of the adult male population.

Astellas has made urology one of its main therapeutic franchises, and has previously said it aims to achieve sales of 170bn yen ($2bn) in this category in fiscal 2014.

EC905 is one of the foundations of that strategy in Europe, extending Astellas' Harnal and Vesicare monotherapy products, which achieved sales of 66.5bn yen ($800m) and 86.7bn yen ($1bn), respectively, in fiscal 2010.

28th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Redbow Consulting Group

Redbow Consulting Group is a specialist healthcare management consultancy specialising in business strategy and marketing...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....